SG11201406974YA - Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus - Google Patents

Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus

Info

Publication number
SG11201406974YA
SG11201406974YA SG11201406974YA SG11201406974YA SG11201406974YA SG 11201406974Y A SG11201406974Y A SG 11201406974YA SG 11201406974Y A SG11201406974Y A SG 11201406974YA SG 11201406974Y A SG11201406974Y A SG 11201406974YA SG 11201406974Y A SG11201406974Y A SG 11201406974YA
Authority
SG
Singapore
Prior art keywords
fusion proteins
vaccinia virus
cells infected
immunoglobulin gene
recombinant vaccinia
Prior art date
Application number
SG11201406974YA
Other languages
English (en)
Inventor
Ernest S Smith
Tracy Pandina
Leslie A Croy
Mark Paris
Maurice Zauderer
Angelika Moksa
Renee Kirk
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of SG11201406974YA publication Critical patent/SG11201406974YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201406974YA 2012-04-26 2013-04-26 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus SG11201406974YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261639046P 2012-04-26 2012-04-26
US201261732776P 2012-12-03 2012-12-03
US13/844,388 US9708601B2 (en) 2012-04-26 2013-03-15 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
PCT/US2013/038497 WO2013163602A1 (en) 2012-04-26 2013-04-26 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus

Publications (1)

Publication Number Publication Date
SG11201406974YA true SG11201406974YA (en) 2014-11-27

Family

ID=49477810

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406974YA SG11201406974YA (en) 2012-04-26 2013-04-26 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus

Country Status (16)

Country Link
US (3) US9708601B2 (ru)
EP (1) EP2841606B1 (ru)
JP (2) JP6498599B2 (ru)
KR (1) KR102108589B1 (ru)
CN (1) CN104520444B (ru)
AU (1) AU2013251371B2 (ru)
CA (1) CA2871597C (ru)
DK (1) DK2841606T3 (ru)
EA (1) EA028164B1 (ru)
ES (1) ES2725673T3 (ru)
IL (1) IL235323B (ru)
NZ (1) NZ630854A (ru)
PL (1) PL2841606T3 (ru)
PT (1) PT2841606T (ru)
SG (1) SG11201406974YA (ru)
WO (1) WO2013163602A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2427212B1 (en) 2009-05-08 2017-08-23 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
PT2766093T (pt) 2011-10-11 2018-05-18 Vaccinex Inc Utilização de moléculas de ligação a semaforina-4d para modulação da permeabilidade da barreira hematoencefálica
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
KR102291971B1 (ko) 2013-06-25 2021-08-19 백시넥스 인코포레이티드 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
SG11201606051YA (en) * 2014-02-19 2016-09-29 Jody Berry Marburg monoclonal antibodies
KR20170019080A (ko) 2015-08-11 2017-02-21 주식회사 엘티전자 플렉시블 사이니지 장치
CN109069628A (zh) * 2016-01-14 2018-12-21 Bps生物科学有限公司 抗pd-1抗体及其用途
AU2017252427B2 (en) 2016-04-22 2023-07-13 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
JP7128177B2 (ja) 2016-08-02 2022-08-30 バクシネックス インコーポレーティッド ワクシニアウイルス／真核細胞においてポリヌクレオチドライブラリを生成するための改善された方法
US11427634B2 (en) * 2017-05-05 2022-08-30 Vaccinex, Inc. Human anti-semaphorin 4D antibody
BR112022022529A2 (pt) 2020-05-06 2023-02-23 Vaccinex Inc Exibição de proteína de membrana integral em vírions envelopados extracelulares de poxvírus
US20240093177A1 (en) 2022-06-10 2024-03-21 Vaccinex, Inc. Methods to select antibodies specific to complex membrane antigens

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445953A (en) 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
AU776865B2 (en) 1998-11-10 2004-09-23 University Of Rochester T cells specific for target antigens and methods and vaccines based thereon
JP2003528605A (ja) 2000-03-28 2003-09-30 ユニヴァーシティー オヴ ロチェスター ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
AU2001297872B2 (en) * 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2002255495A1 (en) 2001-02-02 2002-08-19 University Of Rochester Methods of identifying regulator molecules
EP1413316A1 (en) 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
CA2548180C (en) 2003-12-04 2014-02-04 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
KR101377116B1 (ko) 2004-08-27 2014-03-24 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 면역 및 자가면역의 조절제로서의 세라마이드 유도체
US8022043B2 (en) 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US7858599B2 (en) 2005-12-30 2010-12-28 Hander Robert W Enhancement of urogenital function
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
DE602008004296D1 (de) 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
AU2008219020B2 (en) 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
CN101932333A (zh) 2007-12-26 2010-12-29 瓦西尼斯公司 抗c35抗体联合疗法和方法
WO2010044919A2 (en) 2008-05-28 2010-04-22 Vgx Pharmaceuticals, Inc. Smallpox dna vaccine and the antigens therein that elicit an immune response
US20100081575A1 (en) 2008-09-22 2010-04-01 Robert Anthony Williamson Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
PT2385980T (pt) 2009-01-08 2018-06-26 Albert Einstein College Medicine Inc Vacinas bacterianas com glicolípidos do tipo ceramida associados à parede celular e utilização dos mesmos
EP2427212B1 (en) 2009-05-08 2017-08-23 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
KR101814571B1 (ko) * 2010-03-10 2018-01-04 젠맵 에이/에스 Ｃ―ｍｅｔ에 대한 모노클로날 항체
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
TWI651331B (zh) * 2010-05-04 2019-02-21 戊瑞治療有限公司 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類
AU2011253101A1 (en) * 2010-05-11 2013-01-10 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
NZ604464A (en) 2010-06-14 2014-03-28 Vaccinex Inc Anti-vegf antibodies and uses thereof
CA2804399A1 (en) * 2010-07-06 2012-01-12 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US20130164325A1 (en) 2010-07-07 2013-06-27 Albert Einstein College Of Medicine Of Yeshiva University Ceramide-like glycolipid-associated bacterial vaccines and uses thereof
CN103347896B (zh) 2010-09-02 2017-06-13 瓦西尼斯公司 抗cxcl13抗体和其使用方法
KR102003571B1 (ko) 2011-05-13 2019-07-24 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 골형성 촉진제
PT2766093T (pt) 2011-10-11 2018-05-18 Vaccinex Inc Utilização de moléculas de ligação a semaforina-4d para modulação da permeabilidade da barreira hematoencefálica
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
JP6193275B2 (ja) 2012-03-02 2017-09-06 ヴァクシネックス， インコーポレイテッド Ｂ細胞媒介炎症性疾患を治療するための方法
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
NZ710744A (en) 2013-01-31 2020-07-31 Vaccinex Inc Methods for increasing immunoglobulin a levels
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
KR102291971B1 (ko) 2013-06-25 2021-08-19 백시넥스 인코포레이티드 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
AU2017252427B2 (en) 2016-04-22 2023-07-13 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
JP7128177B2 (ja) 2016-08-02 2022-08-30 バクシネックス インコーポレーティッド ワクシニアウイルス／真核細胞においてポリヌクレオチドライブラリを生成するための改善された方法
JP2020510845A (ja) 2017-02-22 2020-04-09 バクシネックス インコーポレーティッド 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法
EP3600419B1 (en) 2017-03-20 2023-08-09 Vaccinex, Inc. Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
US11427634B2 (en) 2017-05-05 2022-08-30 Vaccinex, Inc. Human anti-semaphorin 4D antibody

Also Published As

Publication number Publication date
CN104520444B (zh) 2017-12-12
KR102108589B1 (ko) 2020-05-07
US9701958B2 (en) 2017-07-11
PL2841606T3 (pl) 2019-07-31
JP6498599B2 (ja) 2019-04-10
CA2871597A1 (en) 2013-10-31
CA2871597C (en) 2021-04-20
ES2725673T3 (es) 2019-09-26
PT2841606T (pt) 2019-05-17
US20160152971A1 (en) 2016-06-02
EP2841606B1 (en) 2019-01-23
US10662422B2 (en) 2020-05-26
KR20150009560A (ko) 2015-01-26
JP2019055956A (ja) 2019-04-11
AU2013251371A1 (en) 2014-11-13
US20170306318A1 (en) 2017-10-26
IL235323A0 (en) 2014-12-31
EP2841606A4 (en) 2015-12-30
EP2841606A1 (en) 2015-03-04
EA028164B1 (ru) 2017-10-31
NZ630854A (en) 2017-03-31
DK2841606T3 (da) 2019-05-06
US20130288927A1 (en) 2013-10-31
WO2013163602A1 (en) 2013-10-31
IL235323B (en) 2020-01-30
US9708601B2 (en) 2017-07-18
JP2015514811A (ja) 2015-05-21
AU2013251371B2 (en) 2018-01-04
EA201491965A1 (ru) 2015-03-31
CN104520444A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
IL235323B (en) Chimeric proteins to aid in the selection of cells infected with vaccinia virus having a specific recombinant immunoglobulin gene
HRP20190574T1 (hr) Poboljšanje anti-kancerogene aktivnosti imunomodulatornih fc fuzijskih proteina
IL275270B (en) Recombinant scavenger cell surface proteins
HK1209439A1 (en) Interleukin-10 fusion proteins and uses thereof -10
PT3744835T (pt) Proteínas de fusão modificadoras do adn e métodos de utilização das mesmas
EP2928924A4 (en) HIV-1 ENV BINDING ANTIBODIES, FUSION PROTEINS AND METHODS OF USE
BR112014024675A8 (pt) célula hospedeira recombinante, cultura celular
HK1198446A1 (en) Anti-vegf single variable domains fused to fc domains fc vegf
PT2858490T (pt) Elementos de adn recombinantes para a expressão de proteínas recombinantes em insetos
SG11201403814RA (en) Production of recombinant proteins with simple glycoforms
HK1207120A1 (en) Improved harvest operations for recombinant proteins
SG10201507721SA (en) CHO-GMT Recombinant Protein Expression
EP2687537A4 (en) POLYPEPTIDE DRUG AGAINST HEPATITIS B VIRUS X PROTEIN
HK1211952A1 (en) Recombinant protein
ZA201504817B (en) Hiv-1 env-binding antibodies, fusion proteins, and methods of use
CO6821887A2 (es) Polipéptido de anticuerpo recombinante anti-cianobasterias, gel del mismo,y método de preparación del mismo
AU2012902684A0 (en) Recombinant Viral Vectors and Uses Therefor
AU2011901988A0 (en) Recombinant viral vaccines